Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study

KAKUHIRO YAMAGUCHI, TAKESHI MASUDA, KAZUNORI FUJITAKA, KEI MIWATA, SHINJIRO SAKAMOTO, YASUSHI HORIMASU, KOSUKE HAMAI, SHINTARO MIYAMOTO, TAKU NAKASHIMA, YOHEI OKAMOTO, HIROSHI IWAMOTO, NOBUHISA ISHIKAWA, YOSHIHIRO MIYATA, MORIHITO OKADA, HIRONOBU HAMADA and NOBORU HATTORI
In Vivo September 2018, 32 (5) 1155-1160; DOI: https://doi.org/10.21873/invivo.11358
KAKUHIRO YAMAGUCHI
1Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKESHI MASUDA
1Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUNORI FUJITAKA
1Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: fujikazu{at}hiroshima-u.ac.jp
KEI MIWATA
1Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHINJIRO SAKAMOTO
1Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YASUSHI HORIMASU
1Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOSUKE HAMAI
2Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHINTARO MIYAMOTO
1Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKU NAKASHIMA
1Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOHEI OKAMOTO
3Nakanohigashi Clinic, Hiroshima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROSHI IWAMOTO
1Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NOBUHISA ISHIKAWA
2Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHIHIRO MIYATA
4Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MORIHITO OKADA
4Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIRONOBU HAMADA
5Department of Physical Analysis and Therapeutic Sciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NOBORU HATTORI
1Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 32 no. 5 1155-1160
DOI 
https://doi.org/10.21873/invivo.11358
PMID 
30150438

Published By 
International Institute of Anticancer Research
Print ISSN 
0258-851X
Online ISSN 
1791-7549
History 
  • Received April 8, 2018
  • Revision received May 21, 2018
  • Accepted May 23, 2018
  • Published online August 27, 2018.

Copyright & License 
Copyright © 2018 The Author(s). Published by the International Institute of Anticancer Research.

Author Information

  1. KAKUHIRO YAMAGUCHI1,
  2. TAKESHI MASUDA1,
  3. KAZUNORI FUJITAKA1,*⇑,
  4. KEI MIWATA1,
  5. SHINJIRO SAKAMOTO1,
  6. YASUSHI HORIMASU1,
  7. KOSUKE HAMAI2,
  8. SHINTARO MIYAMOTO1,
  9. TAKU NAKASHIMA1,
  10. YOHEI OKAMOTO3,
  11. HIROSHI IWAMOTO1,
  12. NOBUHISA ISHIKAWA2,
  13. YOSHIHIRO MIYATA4,
  14. MORIHITO OKADA4,
  15. HIRONOBU HAMADA5 and
  16. NOBORU HATTORI1
  1. 1Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
  2. 2Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan
  3. 3Nakanohigashi Clinic, Hiroshima, Japan
  4. 4Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
  5. 5Department of Physical Analysis and Therapeutic Sciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
  1. Correspondence to: Kazunori Fujitaka, MD, Ph.D., Department of Molecular and Internal Medicine, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. Tel: +81 822575196, Fax: +81 822557360, e-mail: fujikazu{at}hiroshima-u.ac.jp
View Full Text

Statistics from Altmetric.com

Cited By...

  • 6 Citations
  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

In Vivo
Vol. 32, Issue 5
September-October 2018
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
6 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study
KAKUHIRO YAMAGUCHI, TAKESHI MASUDA, KAZUNORI FUJITAKA, KEI MIWATA, SHINJIRO SAKAMOTO, YASUSHI HORIMASU, KOSUKE HAMAI, SHINTARO MIYAMOTO, TAKU NAKASHIMA, YOHEI OKAMOTO, HIROSHI IWAMOTO, NOBUHISA ISHIKAWA, YOSHIHIRO MIYATA, MORIHITO OKADA, HIRONOBU HAMADA, NOBORU HATTORI
In Vivo Sep 2018, 32 (5) 1155-1160; DOI: 10.21873/invivo.11358

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study
KAKUHIRO YAMAGUCHI, TAKESHI MASUDA, KAZUNORI FUJITAKA, KEI MIWATA, SHINJIRO SAKAMOTO, YASUSHI HORIMASU, KOSUKE HAMAI, SHINTARO MIYAMOTO, TAKU NAKASHIMA, YOHEI OKAMOTO, HIROSHI IWAMOTO, NOBUHISA ISHIKAWA, YOSHIHIRO MIYATA, MORIHITO OKADA, HIRONOBU HAMADA, NOBORU HATTORI
In Vivo Sep 2018, 32 (5) 1155-1160; DOI: 10.21873/invivo.11358
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer
  • Prospective Feasibility Study of Amrubicin and Bevacizumab Therapy for Patients With Previously Treated Advanced NSCLC
  • Google Scholar

More in this TOC Section

  • NLRP3 and RANK-RANKL-OPG Pathway-related Gene Expression Levels in Children With Autism Spectrum Disorder
  • Stable “Salivary Viral Road Ratios” in Individuals Infected With Omicron Variants
  • HLA Class I Loss and Resistance to Immunotherapy in Pulmonary Metastasis of Hypopharyngeal Cancer
Show more Clinical Studies

Keywords

  • Bevacizumab
  • salvage therapy
  • non-squamous cell lung cancer
  • osteonecrosis of the jaw
In Vivo

© 2026 In Vivo

Powered by HighWire